domingo, 19 de marzo de 2017

Genomics in CKD: Is This the Path Forward? - PubMed - NCBI

Genomics in CKD: Is This the Path Forward? - PubMed - NCBI



 2016 Mar;23(2):120-4. doi: 10.1053/j.ackd.2016.01.017.

Genomics in CKD: Is This the Path Forward?

Abstract

Recent advances in genomics and sequencing technology have led to a better understanding of genetic risk in CKD. Genetics could account in part for racial differences in treatment response for medications including antihypertensives and immunosuppressive medications due to its correlation with ancestry. However, there is still a substantial lag between generation of this knowledge and its adoption in routine clinical care. This review summarizes the recent advances in genomics and CKD, discusses potential reasons for its underutilization, and highlights potential avenues for application of genomic information to improve clinical care and outcomes in this particularly vulnerable population.

KEYWORDS:

CKD; Disparities; Genetics; Genomics; Pharmacogenomics

PMID:
 
26979150
 
PMCID:
 
PMC4795469
 [Available on 2017-03-01]
 
DOI:
 
10.1053/j.ackd.2016.01.017

[Indexed for MEDLINE] 
Free PMC Article





Last Posted: Mar 10, 2017


No hay comentarios:

Publicar un comentario en la entrada